Analyst Price Targets — ABCL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 10:50 am | — | Stifel Nicolaus | $8.00 | $5.25 | TheFly | AbCellera price target raised to $8 from $7 at Stifel |
| May 5, 2026 10:34 am | — | Cantor Fitzgerald | $7.00 | $4.59 | TheFly | AbCellera initiated with an Overweight at Cantor Fitzgerald |
| November 5, 2024 1:14 pm | Gary Nachman | BMO Capital | $5.00 | $2.74 | StreetInsider | AbCellera Biologics (ABCL) PT Lowered to $5 at BMO Capital |
| August 23, 2024 11:57 am | Scott Schoenhaus | KeyBanc | $5.00 | $2.60 | StreetInsider | KeyBanc Reiterates Overweight Rating on AbCellera Biologics (ABCL) |
| May 8, 2024 2:46 am | Scott Schoenhaus | KeyBanc | $7.00 | $3.84 | StreetInsider | AbCellera Biologics (ABCL) PT Lowered to $7 at KeyBanc |
| January 6, 2023 9:07 am | — | Leerink Partners | $18.00 | $9.63 | Benzinga | SVB Leerink Maintains Outperform on AbCellera Biologics, Lowers Price Target to $18 |
| December 15, 2022 4:41 am | Andrea Tan | Goldman Sachs | $30.00 | $10.13 | TheFly | AbCellera initiated with a Buy at Goldman Sachs |
| November 16, 2022 7:11 am | — | Truist Financial | $29.00 | $14.49 | Benzinga | Truist Securities Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $29 |
| August 10, 2022 8:56 am | — | Credit Suisse | $34.00 | $11.85 | Benzinga | Credit Suisse Maintains Outperform on AbCellera Biologics, Lowers Price Target to $34 |
Latest News for ABCL
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026.
Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Lynn Seely to its Board of Directors.
Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ABCL.
U.S. House Trading
No House trades found for ABCL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.